These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12397544)

  • 41. Defibrillation threshold testing in implantable cardioverter-defibrillators: might less be more than enough?
    Curtis AB
    J Am Coll Cardiol; 2008 Aug; 52(7):557-8. PubMed ID: 18687250
    [No Abstract]   [Full Text] [Related]  

  • 42. Are implantable cardioverter-defribrillators always superior to amiodarone?
    Doggrell SA
    Expert Opin Pharmacother; 2003 Nov; 4(11):2111-4. PubMed ID: 14596664
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiarrhythmic trials: a decade of growth.
    Kanjwal MY
    Indian Heart J; 1998; 50(3):277-84. PubMed ID: 9753848
    [No Abstract]   [Full Text] [Related]  

  • 44. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator.
    Prystowsky EN
    Rev Cardiovasc Med; 2003; 4 Suppl 2():S47-54. PubMed ID: 12776013
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hotline sessions at the 20th European Congress of Cardiology.
    Verheugt FW
    Eur Heart J; 1999 Jan; 20(1):7-10. PubMed ID: 10075136
    [No Abstract]   [Full Text] [Related]  

  • 46. The implantable cardioverter-defibrillator: does everybody need one?
    Raj SR; Sheldon RS
    Prog Cardiovasc Dis; 2001; 44(3):169-94. PubMed ID: 11727276
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
    Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
    Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The shocking story of azimilide.
    Hanna IR; Langberg JJ
    Circulation; 2004 Dec; 110(24):3624-6. PubMed ID: 15596558
    [No Abstract]   [Full Text] [Related]  

  • 49. [The "clinical cost" of implantable cardioverter-defibrillators in the primary prevention of sudden cardiac death is underestimated].
    Disertori M
    G Ital Cardiol (Rome); 2011 May; 12(5):374-8; discussion 378. PubMed ID: 21593957
    [No Abstract]   [Full Text] [Related]  

  • 50. Advantages and pitfalls of combining device-based and pharmacologic therapies for the treatment of ventricular arrhythmias: observations from a tertiary referral center.
    Rajawat YS; Patel VV; Gerstenfeld EP; Nayak H; Marchlinski FE
    Pacing Clin Electrophysiol; 2004 Dec; 27(12):1670-81. PubMed ID: 15613132
    [No Abstract]   [Full Text] [Related]  

  • 51. Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention.
    Das MK; Zipes DP
    J Cardiovasc Pharmacol; 2010 May; 55(5):438-49. PubMed ID: 20509177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Azimilide: another effort to prevent implantable cardioverter-defibrillator shocks and their sequelae why it is important and how it works.
    Cannom DS; Gidney B
    J Am Coll Cardiol; 2008 Sep; 52(13):1084-5. PubMed ID: 18848142
    [No Abstract]   [Full Text] [Related]  

  • 53. [Recent trends in anti-arrhythmia therapy].
    Ogawa S
    Nihon Naika Gakkai Zasshi; 1995 Mar; 84(3):439-41. PubMed ID: 7751785
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators.
    Lancet; 1997 Nov; 350(9089):1417-24. PubMed ID: 9371164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias.
    Reiffel JA
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):333-9. PubMed ID: 11907635
    [No Abstract]   [Full Text] [Related]  

  • 56. [Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Executive summary].
    Zipes DP; Camm AJ; Borggrefe M; Buxton AE; Chaitman B; Fromer M; Gregoratos G; Klein G; Moss AJ; Myerburg RJ; Priori SG; Quinones MA; Roden DM; Silka MJ; Tracy C
    Rev Esp Cardiol; 2006 Dec; 59(12):1328. PubMed ID: 17194428
    [No Abstract]   [Full Text] [Related]  

  • 57. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
    Camm AJ; Pratt CM; Schwartz PJ; Al-Khalidi HR; Spyt MJ; Holroyde MJ; Karam R; Sonnenblick EH; Brum JM;
    Circulation; 2004 Mar; 109(8):990-6. PubMed ID: 14967728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The research practice of anti-arrhythmic agents targeting on potassium ion channel].
    Yang Q; Wang XJ; Tang YQ; You QD
    Yao Xue Xue Bao; 2011 Jan; 46(1):12-8. PubMed ID: 21465803
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical strategies for use of the implantable cardioverter defibrillator: the impact of current trials.
    Estes NA
    Pacing Clin Electrophysiol; 1996 Jul; 19(7):1011-5. PubMed ID: 8823825
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
    Ho AT; Pai SM; Timothy P; Pai RG
    Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.